-
Je něco špatně v tomto záznamu ?
Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet
C. Rognoni, P. Armeni, R. Tarricone, G. Donin,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
- MeSH
- analýza nákladů a výnosů MeSH
- bariatrická chirurgie ekonomika MeSH
- diabetes mellitus ekonomika terapie MeSH
- dieta ekonomika MeSH
- dospělí MeSH
- ekonomické modely * MeSH
- index tělesné hmotnosti MeSH
- kvalita života MeSH
- kvalitativně upravené roky života MeSH
- lidé MeSH
- obezita ekonomika terapie MeSH
- terapie cvičením ekonomika MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
PURPOSE: The aim of the present study was to assess, by using a cost-benefit analysis, the net monetary benefit (NMB) of bariatric surgery compared with diet (including physical exercise) for obese patients, from both an Italian payer perspective and the broader societal perspective. METHODS: The study considered the following groups of patients: (1) patients with a body mass index (BMI) ≥40 kg/m2 without complications + patients with BMI ≥35 kg/m2 with complications; (2) patients with BMI ≥35 kg/m2 and diabetes; and (3) patients with BMI ranging from 30 to 35 kg/m2 and diabetes. A Markov model was developed to project the lifetime health outcomes (life years and quality-adjusted life years [QALYs]) and costs associated with bariatric surgery and diet for the considered groups of patients. The clinical effectiveness of each strategy was based on the likelihood of experiencing cardiovascular events or events related to the presence of diabetes. Data on clinical effectiveness, quality of life, productivity losses, and out-of-pocket costs were mainly derived from the literature; direct costs were obtained from official tariffs or the literature. Different scenarios were considered for the analyses in addition to the base case. According to both perspectives considered, the NMB was calculated by first assuming a willingness-to-pay threshold (30,000€ per QALY), then converting health benefits (QALYs) into the common monetary metric (ie, the euro). NMB was calculated as follows: (incremental benefit × willingness-to-pay - incremental cost). FINDINGS: For all the scenarios and groups of patients considered, the NMB of bariatric surgery versus diet, on a lifetime horizon, from the payer perspective was positive and ranged from 54,647€ to 122,960€; it varied between 141,192€ and 380,286€ from the societal perspective. In the former case, the NMB turns positive after 3-4 years, indicating that bariatric surgery may be a worthy investment also in the short run for the National Health Service; in the latter case, for a time horizon longer than 2-3 years, the surgical option begins to show advantages for the whole society. IMPLICATIONS: Despite its defined cost-effectiveness, bariatric surgery is under-diffused because the initial investment for the technology is often considered a barrier. The cost-benefit analysis showed that bariatric surgery, compared with diet, may be a worthwhile technology for obese patients in Italy from both a payer perspective and the broader societal perspective.
Department of Biomedical Technology Czech Technical University Prague Kladno Czech Republic
Department of Policy Analysis and Public Management Bocconi University Milan Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025293
- 003
- CZ-PrNML
- 005
- 20201222155139.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clinthera.2019.12.001 $2 doi
- 035 __
- $a (PubMed)31959413
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rognoni, Carla $u Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy. Electronic address: carla.rognoni@unibocconi.it.
- 245 10
- $a Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet / $c C. Rognoni, P. Armeni, R. Tarricone, G. Donin,
- 520 9_
- $a PURPOSE: The aim of the present study was to assess, by using a cost-benefit analysis, the net monetary benefit (NMB) of bariatric surgery compared with diet (including physical exercise) for obese patients, from both an Italian payer perspective and the broader societal perspective. METHODS: The study considered the following groups of patients: (1) patients with a body mass index (BMI) ≥40 kg/m2 without complications + patients with BMI ≥35 kg/m2 with complications; (2) patients with BMI ≥35 kg/m2 and diabetes; and (3) patients with BMI ranging from 30 to 35 kg/m2 and diabetes. A Markov model was developed to project the lifetime health outcomes (life years and quality-adjusted life years [QALYs]) and costs associated with bariatric surgery and diet for the considered groups of patients. The clinical effectiveness of each strategy was based on the likelihood of experiencing cardiovascular events or events related to the presence of diabetes. Data on clinical effectiveness, quality of life, productivity losses, and out-of-pocket costs were mainly derived from the literature; direct costs were obtained from official tariffs or the literature. Different scenarios were considered for the analyses in addition to the base case. According to both perspectives considered, the NMB was calculated by first assuming a willingness-to-pay threshold (30,000€ per QALY), then converting health benefits (QALYs) into the common monetary metric (ie, the euro). NMB was calculated as follows: (incremental benefit × willingness-to-pay - incremental cost). FINDINGS: For all the scenarios and groups of patients considered, the NMB of bariatric surgery versus diet, on a lifetime horizon, from the payer perspective was positive and ranged from 54,647€ to 122,960€; it varied between 141,192€ and 380,286€ from the societal perspective. In the former case, the NMB turns positive after 3-4 years, indicating that bariatric surgery may be a worthy investment also in the short run for the National Health Service; in the latter case, for a time horizon longer than 2-3 years, the surgical option begins to show advantages for the whole society. IMPLICATIONS: Despite its defined cost-effectiveness, bariatric surgery is under-diffused because the initial investment for the technology is often considered a barrier. The cost-benefit analysis showed that bariatric surgery, compared with diet, may be a worthwhile technology for obese patients in Italy from both a payer perspective and the broader societal perspective.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a bariatrická chirurgie $x ekonomika $7 D050110
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a analýza nákladů a výnosů $7 D003362
- 650 _2
- $a diabetes mellitus $x ekonomika $x terapie $7 D003920
- 650 _2
- $a dieta $x ekonomika $7 D004032
- 650 _2
- $a terapie cvičením $x ekonomika $7 D005081
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a ekonomické modely $7 D018803
- 650 _2
- $a obezita $x ekonomika $x terapie $7 D009765
- 650 _2
- $a kvalita života $7 D011788
- 650 _2
- $a kvalitativně upravené roky života $7 D019057
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Armeni, Patrizio $u Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy.
- 700 1_
- $a Tarricone, Rosanna $u Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy; Department of Policy Analysis and Public Management, Bocconi University, Milan, Italy.
- 700 1_
- $a Donin, Gleb $u Department of Biomedical Technology, Czech Technical University in Prague, Kladno, Czech Republic.
- 773 0_
- $w MED00001165 $t Clinical therapeutics $x 1879-114X $g Roč. 42, č. 1 (2020), s. 60-75.e7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31959413 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155135 $b ABA008
- 999 __
- $a ok $b bmc $g 1599438 $s 1115979
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 42 $c 1 $d 60-75.e7 $e 20200117 $i 1879-114X $m Clinical therapeutics $n Clin Ther $x MED00001165
- LZP __
- $a Pubmed-20201125